These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1013 related articles for article (PubMed ID: 33620081)

  • 1. 'Blue toes' following vaccination with the BNT162b2 mRNA COVID-19 vaccine.
    Davido B; Mascitti H; Fortier-Beaulieu M; Jaffal K; de Truchis P
    J Travel Med; 2021 Jun; 28(4):. PubMed ID: 33620081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chilblain-like lesions after BNT162b2 mRNA COVID-19 vaccine: a case report suggesting that 'COVID toes' are due to the immune reaction to SARS-CoV-2.
    Lesort C; Kanitakis J; Donzier L; Jullien D
    J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):e630-e632. PubMed ID: 34131969
    [No Abstract]   [Full Text] [Related]  

  • 3. A first case of 'Covid toes' from a viral vector-based COVID-19 vaccine.
    Van Loon A; Mortelmans D; Siozopoulou V; Ogunjimi B; Jansens H; Lambert J; Aerts O
    J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):e400-e402. PubMed ID: 35067975
    [No Abstract]   [Full Text] [Related]  

  • 4. Myocarditis After BNT162b2 and mRNA-1273 Vaccination.
    Larson KF; Ammirati E; Adler ED; Cooper LT; Hong KN; Saponara G; Couri D; Cereda A; Procopio A; Cavalotti C; Oliva F; Sanna T; Ciconte VA; Onyango G; Holmes DR; Borgeson DD
    Circulation; 2021 Aug; 144(6):506-508. PubMed ID: 34133884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea.
    Lee YW; Lim SY; Lee JH; Lim JS; Kim M; Kwon S; Joo J; Kwak SH; Kim EO; Jung J; Kwon HS; Kim TB; Kim SH; Bae S
    J Korean Med Sci; 2021 May; 36(21):e153. PubMed ID: 34060261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Not only toes and fingers: COVID vaccine-induced chilblain-like lesions of the knees.
    Bassi A; Mazzatenta C; Sechi A; Cutrone M; Piccolo V
    J Eur Acad Dermatol Venereol; 2022 Jul; 36(7):e497-e498. PubMed ID: 35188988
    [No Abstract]   [Full Text] [Related]  

  • 7. Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience.
    Kim SH; Wi YM; Yun SY; Ryu JS; Shin JM; Lee EH; Seo KH; Lee SH; Peck KR
    J Korean Med Sci; 2021 Apr; 36(14):e107. PubMed ID: 33847085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea.
    Bae S; Lee YW; Lim SY; Lee JH; Lim JS; Lee S; Park S; Kim SK; Lim YJ; Kim EO; Jung J; Kwon HS; Kim TB; Kim SH
    J Korean Med Sci; 2021 May; 36(17):e115. PubMed ID: 33942579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Herpes Zoster Following COVID-19 Vaccination.
    David E; Landriscina A
    J Drugs Dermatol; 2021 Aug; 20(8):898-900. PubMed ID: 34397201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 vaccines in patients with SLE.
    Tang W; Askanase AD; Khalili L; Merrill JT
    Lupus Sci Med; 2021 Mar; 8(1):. PubMed ID: 33685998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post BNT162b2 mRNA COVID-19 vaccination Henoch-SchÓ§nlein Pupura.
    Wang SSY
    Postgrad Med J; 2022 Dec; 98(1166):900-901. PubMed ID: 35022253
    [No Abstract]   [Full Text] [Related]  

  • 12. Oral lichen planus arising after BNT162b2 mRNA COVID-19 vaccine: report of 2 cases.
    Raccampo L; Sembronio S; Tel A; Cacitti V; Robiony M
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2022 Sep; 134(3):e54-e57. PubMed ID: 35851250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High anaphylaxis rates following vaccination with the Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers: a secondary analysis of initial post-approval safety data.
    Hashimoto T; Ozaki A; Bhandari D; Sawano T; Sah R; Tanimoto T
    J Travel Med; 2021 Oct; 28(7):. PubMed ID: 34128049
    [No Abstract]   [Full Text] [Related]  

  • 14. Immune Thrombocytopenia Following the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine.
    Ganzel C; Ben-Chetrit E
    Isr Med Assoc J; 2021 Jun; 23(6):341. PubMed ID: 34155844
    [No Abstract]   [Full Text] [Related]  

  • 15. Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results.
    Lombardi A; Bozzi G; Ungaro R; Villa S; Castelli V; Mangioni D; Muscatello A; Gori A; Bandera A
    Front Immunol; 2021; 12():657711. PubMed ID: 33777055
    [No Abstract]   [Full Text] [Related]  

  • 16. Keratoplasty Rejection After the BNT162b2 messenger RNA Vaccine.
    Wasser LM; Roditi E; Zadok D; Berkowitz L; Weill Y
    Cornea; 2021 Aug; 40(8):1070-1072. PubMed ID: 34029238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why two doses of the BNT162b2 mRNA COVID-19 vaccine? A different strategy to speed up the vaccination process: single-dose of the BNT162b2 mRNA COVID-19 and other vaccines.
    LA Vecchia C; Centanni S; Gerli AG
    Panminerva Med; 2022 Mar; 64(1):131-132. PubMed ID: 33480519
    [No Abstract]   [Full Text] [Related]  

  • 18. New-onset systemic lupus erythematosus following BNT162b2 mRNA COVID-19 vaccine: a case series and literature review.
    Sagy I; Zeller L; Raviv Y; Porges T; Bieber A; Abu-Shakra M
    Rheumatol Int; 2022 Dec; 42(12):2261-2266. PubMed ID: 36098769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2.
    Au L; Fendler A; Shepherd STC; Rzeniewicz K; Cerrone M; Byrne F; Carlyle E; Edmonds K; Del Rosario L; Shon J; Haynes WA; Ward B; Shum B; Gordon W; Gerard CL; Xie W; Joharatnam-Hogan N; Young K; Pickering L; Furness AJS; Larkin J; Harvey R; Kassiotis G; Gandhi S; ; Swanton C; Fribbens C; Wilkinson KA; Wilkinson RJ; Lau DK; Banerjee S; Starling N; Chau I; ; Turajlic S
    Nat Med; 2021 Aug; 27(8):1362-1366. PubMed ID: 34040262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020.
    Oliver SE; Gargano JW; Marin M; Wallace M; Curran KG; Chamberland M; McClung N; Campos-Outcalt D; Morgan RL; Mbaeyi S; Romero JR; Talbot HK; Lee GM; Bell BP; Dooling K
    MMWR Morb Mortal Wkly Rep; 2020 Dec; 69(50):1922-1924. PubMed ID: 33332292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.